Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

OM Pharma

Add links
From Wikipedia, the free encyclopedia

OM Pharma
TypeSociété Anonyme
IndustryBiopharmaceutical
FoundedBarcelona, (1930)
HeadquartersGeneva, Switzerland
Area served
Worldwide
Key people
  • Roch Ogier (CEO)
Products
OM-89
OwnerEtienne Jornod (Executive Chairman & Co‑Owner)
Number of employees
422
Websitewww.ompharma.com

OM Pharma is a Swiss biopharmaceutical company headquartered in Geneva. The company develops, manufactures and commercialises medicines in areas including respiratory tract infections, urinary tract infections and vascular diseases. It is active in more than 100 countries and its portfolio includes bacterial lysates based products, such as OM-85 and OM-89, as well as other established pharmaceutical products.

In 2020, the company became part of Optimus Holding, led by Etienne Jornod.[1]In 2021, OM Pharma received the Geneva Economy Award.[2]

OM Pharma is the only pharmaceutical company that manufactures in Geneva.[3]

Business and operations

[edit]

OM Pharma’s activities include research and development, manufacturing, commercial operations and partnerships with distributors and marketing organisations. The company works with more than 90 distribution and marketing partners across 100 countries[4].

OM Pharma employs more than 400 people. Its global headquarters and biotech campus are located in Meyrin, Geneva, and the company also has a Swiss affiliate in Villars-sur-Glâne, Fribourg.[5]

The company operates in Latin America through an affiliate in Lima, Peru. It also maintains a sales force in Central America, covering Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama and the Dominican Republic.[6][7]

In 2025, OM Pharma reported CHF 350 million in in-market sales and stated that its core portfolio reached 15.9 million people.[8]

History

[edit]

Origins

[edit]

OM Pharma traces its origins to Barcelona in 1930, when French pharmacist Jean-René Ricard founded a small pharmaceutical laboratory focused on biologically derived medicines. The outbreak of the Spanish Civil War in 1936 forced the Ricard family to leave Spain, and in 1937 the company relocated to Geneva, Switzerland. At that point the business was renamed OM Pharma, with OM standing for the Latin expression Omnia Medicamenta, meaning all medicines.[9]

Integration into CSL Vifor/Galenica

[edit]

In 1970, OM Pharma relocated its main operations to Meyrin, where the company continues to operate. In 2009, it was acquired by Galenica, a part of the Vifor Pharma Group.[10][11][12]

Acquisition by Optimus Holding

[edit]

In 2020, OM Pharma was acquired by Optimus Holding, led by former Vifor Pharma Executive Chairman Etienne Jornod with a consortium of investors.[13] As part of the transaction, Optimus Holding committed to investing over CHF 250 million to enhance the company’s manufacturing and research capabilities.[14] Since 2024, Roch Ogier has served as the company’s CEO.[15]

Products

[edit]

OM Pharma’s products include:

  • Broncho-Vaxom, also known as OM-85, is a bacterial lysate made from 21 bacterial strains. It is used for the prevention of recurrent respiratory tract infections in adults and children.[16][17] In 2025, the product reached more than 5.1 million patients and was registered in 69 countries.
  • Uro-Vaxom, also known as OM-89, is a bacterial lysate derived from 18 strains of Escherichia coli. It is used for recurrent urinary tract infections[18]. In 2025, the product reached more than one million patients and was registered in 53 countries.
  • The company also markets medicines for vascular diseases. These include Doxium, based on calcium dobesilate, indicated in treatment of microangiopathies, signs of chronic venous insufficiencies in the lower limbs, diabetic retinopathy and hemorrhoidal syndrome[19][20], and Dicynone, based on etamsylate, indicated in the treatment of capillary hemorrhages [21].

In Switzerland, OM Pharma markets a wider portfolio of proprietary and in-licensed medicines across several therapeutic areas, including respiratory infections, urology, gynaecology, central nervous system disorders, vascular diseases and hospital care.

Research and development

[edit]

The company’s research programme includes both non-interventional real-world evidence studies and interventional clinical trials.

The REACH study, formally titled Real-World Evidence study of OM-85 in Adults and Children in China, Italy, and Belgium, is a non-interventional study evaluating OM-85 (Broncho-Vaxom®) in routine clinical practice. It is designed to assess the effectiveness of OM-85 in preventing respiratory tract infection episodes and to describe how patients with respiratory tract infections are managed in different healthcare settings.[22]

Preliminary results from the REACH study released at the EAACI 2026 congress show that OM-85 was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy. Further results are expected to be published later in 2026[23] [24].

Clinical trials

[edit]

TIGER: The TIGER study is a randomised, placebo-controlled, 3-arm, double-blind, multicentre, Phase 4 study to assess the efficacy of OM-85 short- and long-term treatment vs. placebo in the prevention of respiratory tract infections in children aged 6-12 years with asthma.[25] About 50 sites are participating across China and Hong Kong.

Broncho-Vaxom Efficacy Assessment in Respiratory tract infections (BEAR): BEAR is a randomised, placebo-controlled, 3-arm, double-blind, multi-centre, Phase 4 study to assess the efficacy of OM-85 (Broncho-Vaxom) short- and long-term treatment vs. placebo in the prevention of respiratory tract infections, in children aged between 6 months and 5 years with wheezing lower respiratory illness.[26] About 40 sites are participating across Europe, including in Hungary, Poland, UK, Switzerland, Italy and Germany.

Efficacy Assessment in recurrent wheezinG chiLdrEn (EAGLE): EAGLE is a randomized, placebo-controlled, double-blind, multicenter, Phase 2b study to assess the efficacy and safety of daily OM-85 treatment vs. placebo in children aged 6 months to 5 years with recurrent wheezing.[27]

References

[edit]
  1. ↑ "Etienne Jornod achète une deuxième fois OM Pharma à Genève - Le Temps" (in French). 18 September 2020. ISSN 1423-3967. Retrieved 30 October 2024.
  2. ↑ "OM Pharma Wins Geneva Economy Award". PharmExec. 21 September 2021. Retrieved 13 November 2024.
  3. ↑ "OM Pharma mise sur la prévention des infections". Entreprise Romande (in French). Retrieved 14 July 2026.
  4. ↑ "Annual Report - OM Pharma | OM Pharma". www.ompharma.com. Retrieved 27 May 2026.
  5. ↑ "Redevenue indépendante, OM Pharma vise les Etats-Unis - Le Temps" (in French). 13 December 2024. ISSN 1423-3967. Retrieved 18 December 2024.
  6. ↑ "OM Pharma situa su filial peruana como hub regional para Latinoamérica". PMFarma. Retrieved 30 October 2024.
  7. ↑ "Farmacéutica | OM Pharma sitúa hub regional en Perú, las razones detrás y negocios a la vista | ECONOMIA". Gestión (in Spanish). 3 May 2023. Retrieved 1 November 2024.
  8. ↑ "Annual Report - OM Pharma | OM Pharma". www.ompharma.com. Retrieved 27 May 2026.
  9. ↑ "OM Pharma fête 80 ans de présence à Meyrin". agefi.com (in French). 2026. Retrieved 14 July 2026.
  10. ↑ "Galenica acquiert la société biotech OM Pharma - Le Temps" (in French). 8 September 2009. ISSN 1423-3967. Retrieved 1 November 2024.
  11. ↑ "BioAlps | 20 years of innovation | OM Pharma". BioAlps. 20 October 2021. Retrieved 30 October 2024.
  12. ↑ "économie - L'entreprise compte 65 % de frontaliers parmi ses 200 collaborateurs. OM Pharma, rescapée genevoise de la pharmaceutique, a 80 ans". www.ledauphine.com (in French). 9 November 2017. Retrieved 1 November 2024.
  13. ↑ "Etienne Jornod, président d'OM Pharma à Genève: «Il ne faut pas baisser le prix des médicaments de façon linéaire» - Le Temps" (in French). 13 December 2024. ISSN 1423-3967. Retrieved 18 December 2024.
  14. ↑ PricewaterhouseCoopers. "Vifor Pharma Group announces successful sale of OM Pharma to Optimus Holding Ltd". PwC. Retrieved 30 October 2024.
  15. ↑ "La Gazette du Laboratoire – OM Pharma nomme Roch Ogier au poste de CEO". www.gazettelabo.fr. Retrieved 1 November 2024.
  16. ↑ "OM85: could bacteria in a capsule protect us from coronavirus and other respiratory infections?". medicine.uq.edu.au. 11 June 2020. Retrieved 14 August 2025.
  17. ↑ Yin, Ju; Xu, Baoping; Zeng, Xiantao; Shen, Kunling (1 January 2018). "Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis". International Immunopharmacology. 54: 198–209. doi:10.1016/j.intimp.2017.10.032. ISSN 1567-5769. PMID 29154122.
  18. ↑ Brodie, Andrew; El-Taji, Omar; Jour, Ibrahim; Foley, Charlotte; Hanbury, Damian (October 2020). "A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89®) for Prophylaxis of Recurrent Urinary Tract Infections". Current Urology. 14 (3): 130–134. doi:10.1159/000499248. ISSN 1661-7649. PMC 7659410. PMID 33224005.
  19. ↑ Allain, Herv??; Ramelet, Albert A; Polard, Elisabeth; Bentu??-Ferrer, Dani??le (2004). "Safety of Calcium Dobesilate in Chronic Venous Disease, Diabetic Retinopathy and Haemorrhoids". Drug Safety. 27 (9): 649–660. doi:10.2165/00002018-200427090-00003. ISSN 0114-5916. PMID 15230646.
  20. ↑ Liu, Jie; Li, Shulin; Sun, Dong (15 March 2019). "Calcium Dobesilate and Micro-vascular diseases". Life Sciences. 221: 348–353. doi:10.1016/j.lfs.2019.02.023. ISSN 1879-0631. PMID 30769115.
  21. ↑ Garay, Ricardo P.; Chiavaroli, Carlo; Hannaert, Patrick (2006). "Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent". American Journal of Therapeutics. 13 (3): 236–247. doi:10.1097/01.mjt.0000158336.62740.54. ISSN 1075-2765. PMID 16772766.
  22. ↑ "REACH study: Real-World Evidence study of OM-85 in Adults and Children in China, Italy, and Belgium | HMA-EMA Catalogues of real-world data sources and studies". catalogues.ema.europa.eu. Retrieved 27 May 2026.
  23. ↑ "OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026 | Business Wire". kommunikasjon.ntb.no (in Norwegian). Retrieved 14 July 2026.
  24. ↑ Read, 8 Min (15 June 2026). "OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026". BioSpace. Retrieved 14 July 2026.{{cite web}}: CS1 maint: numeric names: authors list (link)
  25. ↑ "China drug trials". www.chinadrugtrials.org.cn. Retrieved 27 March 2026.
  26. ↑ OM Pharma SA (23 March 2026). A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho-Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years With Wheezing Lower Respiratory Illness (Report). clinicaltrials.gov.
  27. ↑ OM Pharma SA (19 February 2026). A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo Given in Children Aged 6 Months to 5 Years With Recurrent Wheezing (Report). clinicaltrials.gov.
Retrieved from "https://en.wikipedia.org/w/index.php?title=OM_Pharma&oldid=1365589039"